疫苗是人类伟大的发明之一,拯救了无数的生命并改善了全世界人民的健康。随着人口的增长和微生物适应性的提高,全球疫苗市场的需求越来越高。尤其是自2019年底新冠疫情爆发以来,在全球范围内展开了一场协同作战的疫苗竞赛:从发现新冠病毒后短短一年的时间里,新冠疫苗研发得到了空前的发展,其中包括mRNA疫苗、病毒载体疫苗和基于蛋白质的疫苗等。
准确、非标记的分子定量及动力学分析是高效疫苗研发的基础,满足所需的分析通量是早期发现和工艺开发的主要挑战。赛多利斯Octet®非标记分子互作分析系统具备高通量、易于操作、分析精度高的特点,通过免标记的生物层干涉(BLI)技术和灵活多样的生物传感器,提供实时的结合动力学、特异性及亲和力、免疫反应、表位图谱以及疫苗滴度等信息,以快速了解抗原靶点及疫苗候选药物特征。
观看
视频
作为成熟的分析方法,Octet®已协助多种疫苗的研究和开发(详见表1),并应用于多个关键环节,包括表位设计、识别及特征分析,病原体多样性和分布,抗体亲和力测定,宿主免疫反应特征、多样性和分布,核酸和分子病原体-宿主相互作用研究,以及治疗药物及临床研究等。
表1. 使用Octet®进行疫苗研究和开发的文献汇总
↓滑动查看
疾病 |
病原体类型 |
参考文献编号 |
COVID-19 |
SARS-CoV-2冠状病毒(病毒) |
1 |
HIV |
慢病毒(病毒) |
2 |
流感 |
正粘病毒(病毒) |
3 |
埃博拉 |
丝状病毒(病毒) |
4 |
登革热 |
黄病毒(病毒) |
5 |
天花 |
痘苗病毒(病毒) |
6 |
葡萄球菌感染 |
金黄色葡萄球菌(细菌) |
7 |
疟疾 |
恶性疟原虫(原生动物) |
8 |
基孔肯雅热 |
基孔肯雅病毒(病毒) |
9 |
结核病 |
结核分枝杆菌(细菌) |
10 |
中东呼吸综合征MERS |
MERS-CoV冠状病毒(病毒) |
11 |
丙型肝炎HCV |
丙肝病毒(病毒) |
- |
炭疽 |
炭疽芽孢杆菌(细菌) |
12 |
寨卡病毒 |
黄病毒(病毒) |
13 |
疱疹病毒 |
疱疹病毒(病毒) |
14 |
上呼吸道感染 |
人呼吸道合胞病毒(病毒) |
15 |
手足口病 |
肠道病毒71型(病毒) |
16 |
HMPV |
人偏肺病毒(病毒) |
17 |
血吸虫病 |
日本血吸虫(扁形动物门) |
18 |
新生儿巨细胞病毒感染 |
巨细胞病毒(病毒) |
19 |
百日咳 |
百日咳杆菌(细菌) |
20 |
艰难梭菌感染 |
艰难梭状芽胞杆菌(细菌) |
21 |
马尔堡病毒 |
丝状病毒(病毒) |
22 |
白喉 |
白喉杆菌(细菌) |
23 |
胃肠炎&脑膜炎 |
大肠杆菌(细菌) |
24 |
李斯特菌病 |
李斯特杆菌(细菌) |
25 |
肺部感染 |
绿脓杆菌(细菌) |
26 |
急性中耳炎 |
卡他莫拉菌(细菌) |
27 |
阴道炎 |
阴道滴虫(原生动物) |
28 |
衣原体感染 |
沙眼衣原体(细菌) |
29 |
肺,尿路感染 |
肺炎克雷伯氏菌(细菌) |
30 |
脑膜炎 |
JEV(病毒) |
31 |
本期在线讲座,来自赛多利斯生物分析部门的高级应用经理陈涛老师将为大家介绍基于非标记分子互作技术的高效疫苗研发策略。
主讲内容
生物层干涉技术(BLI) 及Octet®分子互作系统介绍
Octet®用于疫苗研究及开发的原理与优势
Octet®高效疫苗研发案例分享
活动时间
2022/3/24 15:00-16:00
主讲嘉宾
陈涛
赛多利斯生物分析高级应用经理,从事生物层干涉技术(BLI)类产品的技术支持12年,有着丰富的Octet®使用和troubleshooting经验,承担了国内华东地区现有客户的售后支持,并多次举办了在线培训和其他各种形式的培训班。在他的支持下,目前仅国内利用生物层干涉技术发表的SCI就有500余篇,是互作技术领域非常知名的“陈老师”
扫码注册
-参考文献- 滑动查看 ▼
https://www.medrxiv.org/content/10.1101/2021.09.02.21261735v1.
Asokan, M.; Rudicell, R.S.; Louder, M.; McKee, K.; O’Dell, S.; Stewart-Jones, G.; Wang, K.; Xu, L.; Chen, X.; Choe, M.; et al. Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization. J. Virol. 2015, 89, 12501–12512.
Li, Z.N.;Weber, K.M.; Limmer, R.A.; Horne, B.J.; Stevens, J.; Schwerzmann, J.;Wrammert, J.; McCausland, M.; Phipps, A.J.; Hancock, K.; et al. Evaluation of multiplex assay platforms for detection of influenza hemagglutinin subtype specific antibody responses. J. Virol. Methods 2017, 243, 61–67.
Bornholdt, Z.A.; Turner, H.L.; Murin, C.D.; Li,W.; Sok, D.; Souders, C.A.; Piper, A.E.; Goff, A.; Shamblin, J.D.; Wollen, S.E.; et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 2016, 351, 1078–1083.
Costin, J.M.; Jenwitheesuk, E.; Lok, S.-M.; Hunsperger, E.; Conrads, K.A.; Fontaine, K.A.; Rees, C.R.; Rossmann, M.G.; Isern, S.; Samudrala, R.; et al. Structural Optimization and De Novo Design of Dengue Virus Entry Inhibitory Peptides. PLoS Negl. Trop. Dis. 2010, 4, e721.
Kaever, T.; Meng, X.; Matho, M.H.; Schlossman, A.; Li, S.; Sela-Culang, I.; Ofran, Y.; Buller, M.; Crump, R.W.; Parker, S.; et al. Potent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 Protein. J. Virol. 2014, 88, 11339–11355.
Hawkins, J.; Kodali, S.; Matsuka, Y.V.; McNeil, L.K.; Mininni, T.; Scully, I.L.; Vernachio, J.H.; Severina, E.; Girgenti, D.; Jansen, K.U.; et al. A Recombinant Clumping Factor A-Containing Vaccine Induces Functional Antibodies to Staphylococcus aureus That Are Not Observed after Natural Exposure. Clin. Vaccine Immun. 2012, 19, 1641–1650.
Douglas, A.D.; Baldeviano, G.C.; Lucas, C.M.; Lugo-Roman, L.A.; Crosnier, C.; Bartholdson, S.J.; Diouf, A.; Miura, K.; Lambert, L.E.; Ventocilla, J.A.; et al. A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys. Cell Host Microbe 2015, 17, 130–139.
Selvarajah, S.; Sexton, N.R.; Kahle, K.M.; Fong, R.H.; Mattia, K.-A.; Gardner, J.; Lu, K.; Liss, N.M.; Salvador, B.; Tucker, D.F.; et al. A Neutralizing Monoclonal Antibody Targeting the Acid-Sensitive Region in Chikungunya Virus E2 Protects from Disease. PLoS Negl. Trop. Dis. 2013, 7, e2423.
Roy, S.; Ly, D.; Li, N.S.; Altman, J.D.; Piccirilli, J.A.; Moody, D.B.; Adams, E.J. Molecular basis of mycobacterial lipid antigen presentation by CD1c and its recognition by T cells. Proc. Natl. Acad. Sci. USA 2014, 11, E4648–E4657.
Wang, L.; Shi, W.; Joyce, M.G.; Modjarrad, K.; Zhang, Y.; Leung, K.; Lees, C.R.; Zhou, T.; Yassine, H.M.; Kanekiyo, M.; et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun. 2015, 6, 7712.
Chi, X.; Li, J.; Liu, W.; Wang, X.; Yin, K.; Liu, J.; Zai, X.; Li, L.; Song, X.; Zhang, J.; et al. Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine. J. Clin. Vaccine Immun. 2015, 22, 553–560.
Barba-Spaeth, G.; Dejnirattisai, W.; Rouvinski, A.; Vaney, M.C.; Medits, I.; Sharma, A.; Simon-Lorière, E.; Sakuntabhai, A.; Cao-Lormeau, V.M.; Haouz, A.; et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 2016, 536, 48–53.
Cairns, T.M.; Huang, Z.-Y.; Gallagher, J.R.; Lin, Y.; Lou, H.; Whitbeck, J.C.; Wald, A.; Cohen, G.H.; Eisenberg, R.J. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific. J. Virol. 2015, 89, 9213–9231.
Krarup, A.; Truan, D.; Furmanova-Hollenstein, P.; Bogaert, L.; Bouchier, P.; Bisschop, I.J.M.; Widjojoatmodjo, M.N.; Zahn, R.; Schuitemaker, H.; McLellan, J.S.; et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 2015, 6, 8143.
Fan, P.; Li, X.; Sun, S.; Su,W.; An, D.; Gao, F.; Kong,W.; Jiang, C. Identification of a Common Epitope between Enterovirus 71 and Human MED25 Proteins Which May Explain Virus-Associated Neurological Disease. Viruses 2015, 7, 1558–1577.
Schuster, J.E.; Cox, R.G.; Hastings, A.K.; Boyd, K.L.; Wadia, J.; Chen, Z.; Burton, D.R.; Williamson, R.A.; Williams, J.V. A Broadly Neutralizing Human Monoclonal Antibody Exhibits In Vivo Efficacy against Both Human Metapneumovirus and Respiratory Syncytial Virus. J. Infect. Dis. 2015, 211, 216–225.
You, H.; Gobert, G.N.; Cai, P.; Mou, R.; Nawaratna, S.; Fang, G.; Villinger, F.; McManus, D.P. Suppression of the Insulin Receptors in Adult Schistosoma japonicum Impacts on Parasite Growth and Development: Further Evidence of Vaccine Potential. PLoS Negl. Trop. Dis. 2015, 9, e0003730.
Kauvar, L.M.; Liu, K.; Park, M.; DeChene, N.; Stephenson, R.; Tenorio, E.; Ellsworth, S.L.; Tabata, T.; Petitt, M.; Tsuge, M.; et al. A High-Affinity Native Human Antibody Neutralizes Human Cytomegalovirus Infection of Diverse Cell Types. Antimicrob. Agents Chemother. 2015, 59, 1558–1568.
Millen, H.;Watanabe, M.; Komatsu, E.; Yamaguchi, F.; Nagasawa, Y.; Suzuki, E.; Monaco, H.;Weiss, A. Single Amino Acid Polymorphisms of Pertussis Toxin Subunit S2 (PtxB) Affect Protein Function. PLoS ONE 2015, 10, e0137379.
Anosova, N.G.; Cole, L.E.; Li, L.; Zhang, J.; Brown, A.M.; Mundle, S.; Zhang, J.; Ray, S.; Ma, F.; Garrone, P.; et al. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model. Clin. Vaccine Immunol. 2015, 22, 711–725.
Flyak, A.I.; Ilinykh, P.A.; Murin, C.D.; Garron, T.; Shen, X.; Fusco, M.L.; Hashiguchi, T.; Bornholdt, Z.A.; Slaughter, J.C.; Sapparapu, G.; et al. Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus. Cell 2015, 160, 893–903.
Sevigny, L.M.; Booth, B.J.; Rowley, K.J.; Leav, B.A.; Cheslock, P.S.; Garrity, K.A.; Sloan, S.E.; Thomas,W., Jr. Babcock, G.J.; Wang, Y. Identification of a Human Monoclonal Antibody to Replace Equine Diphtheria Antitoxin for Treatment of Diphtheria Intoxication. Infect. Immun. 2013, 81, 3992–4000.
Szijártó, V.; Guachalla, L.M.; Visram, Z.C.; Hartl, K.; Varga, C.; Mirkina, I.; Zmajkovic, J.; Badarau, A.; Gerhild, Z.; Pleban, C.; et al. Bactericidal Monoclonal Antibodies Specific to the Lipopolysaccharide O Antigen from Multidrug-Resistant Escherichia coli Clone ST131-O25b:H4 Elicit Protection in Mice. Antimicrob. Agents Chemother. 2015, 59, 3109–3116.
Reniere, M.L.; Whiteley, A.T.; Hamilton, K.L.; John, S.M.; Lauer, P.; Brennan, R.G.; Portnoy, D.A. Glutathione activates virulence gene expression of an intracellular pathogen. Nature 2015, 517, 170–173.
DiGiandomenico, A.; Warrener, P.; Hamilton, M.; Guillard, S.; Ravn, P.; Minter, R.; Camara, M.M.; Venkatraman, V.; Macgill, R.S.; Lin, J.; et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening. J. Exp. Med. 2012, 209, 1273–1287.
Singh, B.; Al-Jubair, T.; Voraganti, C.; Andersson, T.; Mukherjee, O.; Su, Y.-C.; Zipfel, P.; Riesbeck, K. Moraxella catarrhalis Binds Plasminogen to Evade Host Innate Immunity. Infect. Immun. 2015, 83, 3458–3469.
Fichorova, R.N.; Yamamoto, H.S.; Fashemi, T.; Foley, E.; Ryan, S.; Beatty, N.; Dawood, H.; Hayes, G.R.; St-Pierre, G.; Sato, S.; et al. Trichomonas vaginalis. Lipophosphoglycan Exploits Binding to Galectin-1 and -3 to Modulate Epithelial Immunity. J. Biol. Chem. 2016, 291, 998–1013.
Hou, S.; Dong, X.; Yang, Z.; Li, Z.; Liu, Q.; Zhong, G. Chlamydial Plasmid-Encoded Virulence Factor Pgp3 Neutralizes the Antichlamydial Activity of Human Cathelicidin LL-37. Infect. Immun. 2015, 83, 4701–4709.
Wang, Q.; Chen, Y.; Cvitkovic, R.; Pennini, M.E.; Chang, C.S.; Pelletier, M.; Bonnell, J.; Koksal, A.C.; Wu, H.; Dall’Acqua,W.F.; et al. Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA. PLoS ONE 2017, 12, e0170529.
Zu, X.; Liu, Y.;Wang, S.; Jin, R.; Zhou, Z.; Liu, H.; Gong, R.; Xiao, G.F.;Wang,W. Peptide inhibitor of Japanese encephalitis virus infection targeting envelope protein domain III. Antivir. Res. 2014, 104, 7–14.
识别微信二识别微信二维码,添加生物制品圈小编,符合条件者即可加入生物制品微信群!
请注明:姓名+研究方向!
本公众号所有转载文章系出于传递更多信息之目的,且明确注明来源和作者,不希望被转载的媒体或个人可与我们联系(cbplib@163.com),我们将立即进行删除处理。所有文章仅代表作者观点,不代表本站立场。